# Weight-Loss Jab Plus Antibody: Less Lean Mass Lost

_Evidence Level: Moderate · Mosenzon O et al., Lancet (London, England), DOI 10.1016/S0140-6736(26)01953-7_

*Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.*

- **Evidence Level**: Moderate
- **Why this grade**: A double-blind trial with random assignment of 975 people over 26 to 52 weeks, but it measured body composition, not strength or health.
- **Facts**: Design: Randomized controlled trial · Duration: 6 months · Funding: Regeneron Pharmaceuticals, Inc.
- **Publication Types**: Journal Article
- **Journal**: Lancet (London, England)
- **Sample Size**: 975 adults with obesity in the US
- **Authors**: Mosenzon O, Rosenstock J, Raya JG, Grimsby JS, Calle RA, Cannon K, Haggag AZ, Bays H, Sarkar N, Templeton A, Fanous M, Lighter J, Vavere A, Yancopoulos GD, Hirshberg B
- **Graded and published**: 2026-11-11
- **Last edited**: 2026-11-20
- **Topics**: GLP-1, Muscle Health, Longevity Drugs
- **DOI**: https://doi.org/10.1016/S0140-6736(26)01953-7
- **Original Source**: https://pubmed.ncbi.nlm.nih.gov/43014326/
- **Registration**: ClinicalTrials.gov NCT06299098 (https://clinicaltrials.gov/study/NCT06299098)

## Summary

Fast weight loss on drugs like semaglutide also strips away a lot of muscle, the researchers write. Adding an antibody called trevogrumab slowed that loss. The antibody blocks myostatin, a natural signal in the body that holds back muscle growth.

At 60 sites in the US, adults with obesity took weekly semaglutide for half a year. They were chosen at random to also get trevogrumab, trevogrumab plus a second antibody called garetosmab, or a dummy treatment. With the dummy, lean mass, mostly muscle, shrank by 6.6 percent. With trevogrumab, the loss was about 3 percentage points smaller. In a second, year-long part of the study, the higher dose showed the same effect.

The two-antibody combination also melted away more fat, but people tolerated it poorly. Almost a third stopped treatment, and many had muscle cramps. Two people died, and the researchers found no link to the treatment. Whether the preserved lean mass means more strength is not yet clear: the trial measured body composition, not function.

## Practical Takeaway

Trevogrumab reduced lean mass loss during semaglutide treatment, while adding garetosmab caused poor tolerability.

---

_Canonical: https://longevity-cities.com/en/research/weight-loss-jab-plus-antibody-less-lean-mass-lost · Part of Longevity Cities · Updated 2026-11-20_
